Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) Products under Development by Stage of Development | 8 | 1 |
| Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) Products under Development by Therapy Area | 9 | 1 |
| Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) Products under Development by Indication | 10 | 2 |
| Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) Products under Development by Companies | 14 | 3 |
| Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) Companies Involved in Therapeutics Development | 23 | 9 |
| Constellation Pharmaceuticals, Inc. | 23 | 1 |
| Daiichi Sankyo Company, Limited | 24 | 1 |
| Domainex Limited | 25 | 1 |
| EpiZyme, Inc. | 26 | 1 |
| GlaxoSmithKline Plc | 27 | 1 |
| Kainos Medicine, Inc. | 28 | 1 |
| Pfizer Inc. | 29 | 1 |
| Transgene Biotek Limited | 30 | 1 |
| UNC Health Care | 31 | 1 |
| Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) Drug Profiles | 32 | 20 |
| CPI-1205 Drug Profile | 32 | 1 |
| CPI-169 Drug Profile | 33 | 1 |
| EBI-2554 Drug Profile | 34 | 1 |
| EPZ-5687 Drug Profile | 35 | 1 |
| GSK-2816126 Drug Profile | 36 | 1 |
| GSK-343 Drug Profile | 37 | 1 |
| JQEZ-5 Drug Profile | 38 | 1 |
| KM-301 Drug Profile | 39 | 1 |
| Small Molecule to Inhibit EZH2 for Oncology Drug Profile | 40 | 1 |
| Small Molecules to Inhibit EZH 1/2 for Oncology Drug Profile | 41 | 1 |
| Small Molecules to Inhibit EZH2 for Oncology Drug Profile | 42 | 1 |
| Small Molecules to Inhibit EZH2-EED for Oncology Drug Profile | 43 | 1 |
| tazemetostat Drug Profile | 44 | 7 |
| TBL-0404 Drug Profile | 51 | 1 |
| Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) Dormant Projects | 52 | 1 |
| Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) Featured News &Press Releases | 53 | 18 |
| Jun 19, 2016: Epizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting | 53 | 1 |
| May 12, 2016: Epizyme to Present Data From the Tazemetostat Non-Hodgkin Lymphoma Program at American Society for Hematology Meeting on Lymphoma Biology | 54 | 1 |
| May 04, 2016: Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Mesothelioma | 55 | 1 |
| May 03, 2016: New investigational compound shows promise against melanoma, lymphoma | 56 | 1 |
| Apr 18, 2016: Epizyme Presents Data from Tazemetostat Clinical Pharmacology Studies at American Association for Cancer Research Annual Meeting 2016 | 57 | 1 |
| Mar 17, 2016: Epizyme to Present New Data in Support of Tazemetostat Clinical Development Program | 58 | 1 |
| Mar 09, 2016: Epizyme Unveils Corporate Strategy to Guide Efforts over Next Five Years | 59 | 2 |
| Feb 08, 2016: Epizyme Announces Tazemetostat Granted Orphan Drug Designation for Malignant Rhabdoid Tumors by U.S. FDA | 61 | 1 |
| Dec 30, 2015: Epizyme Announces First Patient Dosed in Global Clinical Program Evaluating Tazemetostat in Genetically Defined Solid Tumors | 62 | 1 |
| Dec 28, 2015: Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Diffuse Large B-cell Lymphoma | 63 | 1 |
| Dec 07, 2015: Epizyme Presents Updated Data from Ongoing Phase 1 Study of Tazemetostat Showing Objective, Durable Responses in Relapsed or Refractory Non-Hodgkin Lymphoma | 64 | 1 |
| Nov 05, 2015: Epizyme Announces phase 1 study data on Tazemetostat at 57th American Society of Hematology Annual Meeting | 65 | 1 |
| Nov 04, 2015: Epizyme to Present New Scientific Data on the Role of HMT Inhibitors in Cancer | 66 | 2 |
| Sep 26, 2015: Epizyme Announces Updated Tazemetostat Phase 1 Data Showing Clinical Activity in a Broader Range of Adults With INI1-Negative and SMARCA4-Negative Solid Tumors | 68 | 2 |
| Sep 26, 2015: Epizyme to Present Clinical Data from Ongoing Phase 1 Dose Escalation Trial of Tazemetostat at the European Cancer Congress | 70 | 1 |
| Appendix | 71 | 2 |
| Methodology | 71 | 1 |
| Coverage | 71 | 1 |
| Secondary Research | 71 | 1 |
| Primary Research | 71 | 1 |
| Expert Panel Validation | 71 | 1 |
| Contact Us | 71 | 1 |
| Disclaimer | 72 | 1 |
